Orlistat-d3
Product Specifications
UNSPSC Description
Orlistat-d3 is a deuterated labeled Orlistat[1]. Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity[2].?Anti-atherosclerotic?effect[3].
Target Antigen
Apoptosis; Fatty Acid Synthase (FASN); Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis;Metabolic Enzyme/Protease;Others
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Smiles
O=C1[C@@H](CCCCCC)[C@H](C[C@@H](OC([C@@H](NC([H])=O)CC(C)C([2H])([2H])[2H])=O)CCCCCCCCCCC)O1
Molecular Weight
498.75
References & Citations
[1]Giorgia Cioccoloni, et al. Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro. Int J Oncol. 2015 Aug;47(2):764-72.|[2]Zaidatul Akmal Othman, et al. Anti-Atherogenic Effects of Orlistat on Obesity-Induced Vascular Oxidative Stress Rat Model. Antioxidants (Basel). 2021 Feb 6;10(2):251.|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
Shipping Conditions
Room temperature
Clinical Information
No Development Reported
CAS Number
1356930-46-5
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
